Leland Stanford Junior University

Gigagen, Inc.

Everett Hurteau Meyer

David Scott Johnson

Samuel Strober

Dale T Umetsu

Rosemarie Dekruyff

Panagiota Iliopoulou

Yuchiao Hsu

Magdiel Pérez Cruz

Robert S Negrin

Stuart Barry Goodman

Tzuhua Dennis Lin

Sai-Wen Tang

Magdiel Perez Cruz

The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.

Methods for allogenic hematopoietic stem cell transplantation

Methods and systems are provided for massively parallel genetic analysis of single cells in emulsion droplets or reaction containers. Genetic loci of interest are targeted in a single cell using a set of probes, and a fusion complex is formed by molecular linkage and amplification techniques. Methods are provided for high-throughput, massively parallel analysis of the fusion complex in a single cell in a population of at least 10,000 cells. Also provided are methods for tracing genetic information back to a cell using barcode sequences.

System and methods for massively parallel analysis of nucleic acids in single cells

Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.

Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases

RGMb antagonists reduce undesirable immune responses associated with tissue or organ transplantation.

Blockade of RGMB for reducing transplantation-associated inflammation leading to loss of function of a transplanted organ in a graft recipient

Blockade of RGMb for reducing transplantation-associated immune responses

Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example &#x3b2;-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.

Methods for relieving asthma-associated airway hyperresponsiveness

Methods for inhibition of NKT cells

Growing community of inventors

Redwood City, CA, United States of America

Everett Hurteau Meyer